Annual report pursuant to Section 13 and 15(d)

Earnings (Loss) Per Common Share (Details)

v3.20.2
Earnings (Loss) Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2020
Jun. 30, 2020
Jun. 30, 2019
Basic and diluted numerator:        
Net loss attributable to iBio, Inc.     $ (16,439) $ (17,593)
Deemed dividends - down round of Series A Preferred and Series B Preferred     (21,560) 0
Preferred stock dividends - iBio CMO Preferred Tracking Stock     (261) (260)
Net loss available to iBio, Inc. stockholders     $ (38,260) $ (17,853)
Basic and diluted denominator:        
Weighted-average common shares outstanding 79,719 47,018 62,795 18,926
Per share amount $ (0.06) $ (0.74) $ (0.61) $ (0.94)